I-Mab (NASDAQ:IMAB) has submitted
an Investigational New Drug (IND) application in South Korea to
evaluate the safety and efficacy of TJM2 in treating cytokine storm (CS)
in COVID-19 patients.
TJM2 is a neutralizing antibody against human
granulocyte-macrophage colony stimulating factor (GM-CSF), an important
cytokine that plays a critical role in acute and chronic inflammation.
The IND submission follows the announcement plans of a similar program initiated by I-Mab in the U.S.
The results from COVID-19 CS study will also be
used to further evaluate the potential therapeutic role of TJM2 in
reducing or preventing CS and neurotoxicity associated with CAR-T
therapy.
Shares are up 8% premarket.
https://seekingalpha.com/news/3556261-i-mab-submits-ind-in-south-korea-for-tjm2-in-covidminus-19-shares-up-8-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.